investors

Press Releases

DateTitle and SummaryView
May 15, 2017
-Company Considering Potential Strategic Alternatives for ICT-107-
ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results
March 23, 2017
LOS ANGELES and HOUSTON , March 23, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) and Memgen, LLC ("Memgen") announce the signing of a non-binding letter of intent to exclusively negotiate the terms  to possibly establish an immuno-oncology strategic
ImmunoCellular Therapeutics and Memgen Announce Letter of Intent for Potential Joint Immuno-Oncology Collaboration
March 14, 2017
LOS ANGELES , March 14, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2016 filed with the Securities and Exchange Commission on March 9,
ImmunoCellular Therapeutics Receives Audit Opinion With Going Concern Explanation
March 9, 2017
LOS ANGELES , March 9, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the fourth quarter and full year 2016 and provided a corporate update.  Anthony Gringeri , PhD, ImmunoCellular's President and Chief Executive
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
March 6, 2017
LOS ANGELES , March 6, 2017 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced that it plans to report fourth quarter and full year 2016 financial results on Thursday, March 9, 2017 . The Company also plans to hold a conference call and webcast
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on March 9, 2017
March 6, 2017
- ICT-107 Protocol Amendment Being Implemented in US Clinical Sites; Amended Protocol Submissions Underway in Europe and Canada.
- Successful Sequencing of Target T Cell Receptor Gene is Key Step in Advancing toward Identification of Potential Clinical Candidate in Stem-to-T-Cell Program.
ImmunoCellular Therapeutics Provides Update on ICT-107 Phase 3 Glioblastoma Trial and Announces Advances in Stem-to-T-Cell Research Program
December 14, 2016
LOS ANGELES , Dec. 14, 2016 /PRNewswire/ --  ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT:IMUC) announced today that the Board of Directors has appointed Anthony Gringeri , PhD, as Chief Executive Officer and a member of the Board of Directors. Dr.
ImmunoCellular Therapeutics Announces Management Changes
November 21, 2016
Long-Term Survival Data Reported from Phase 1 ICT-107 Trial
ImmunoCellular Therapeutics Reports Updated Immune Monitoring Data from ICT-107 Phase 2 Trial in Newly Diagnosed Glioblastoma at the Society for Neuro-Oncology Annual Meeting 2016
November 16, 2016
LOS ANGELES , Nov. 16, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular " or the "Company") (NYSE MKT: IMUC) announced that at the Special Meeting of Stockholders held on November 14, 2016 , ImmunoCellular's stockholders voted to approve a reverse stock split of the
ImmunoCellular Therapeutics Announces One-for-Forty Reverse Stock Split
November 10, 2016
LOS ANGELES , Nov. 10, 2016 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. (" ImmunoCellular ") (NYSE MKT: IMUC) today announced financial results for the third quarter of 2016 and provided an update on its research and development activities.  Andrew Gengos , ImmunoCellular's Chief Executive
ImmunoCellular Therapeutics Announces Third Quarter 2016 Financial Results and Provides Research and Development Update
Copyright 2018 by Immunocellular Therapeutics, Ltd.
All Rights Reserved